左旋多巴联合恩他卡朋在帕金森病患者中的应用效果及安全性  

Analysis of the effect and safety of levodopa combined with entacapone in patients with Parkinson's disease

作　　者：白新涛[1] BAI Xintao(The Second Affiliated Hospitalof Henan University of Science and Technology,Luoyang 471000,China)

机构地区：[1]河南科技大学第二附属医院,河南洛阳471000

出　　处：《中国实用神经疾病杂志》2020年第10期885-888,共4页Chinese Journal of Practical Nervous Diseases

摘　　要：目的分析左旋多巴联合恩他卡朋在帕金森病患者中的应用效果及安全性。方法选择2018—2019年在河南科技大学第二附属医院治疗的帕金森病患者78例,随机化原则分为2组,各39例。对照组给予左旋多巴治疗,观察组在对照组基础上加用恩他卡朋治疗,比较2组血清指标、帕金森评分量表-Ⅱ(UPDRS-Ⅱ)、UPDRS-Ⅲ评分及不良反应情况。结果治疗后,观察组白细胞介素-1β(IL-1β)、IL-6、丙二醛(MDA)水平均明显低于对照组,超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)水平较高,差异有统计学意义(P<0.05);与对照组治疗后比较,观察组UPDRS-Ⅱ、UPDRS-Ⅲ评分均较低,差异有统计学意义(P<0.05);观察组不良反应发生率(10.25%)与对照组(15.38%)比较,差异无统计学意义(P>0.05)。结论左旋多巴联合恩他卡朋治疗帕金森病效果较好,可有效改善患者血清水平,提高帕金森量表评分,且未增加不良反应发生率。Objective To analyze the effect and safety of levodopa combined with entacapone in patients with Parkinson's disease.Methods Seventy-eight patients with Parkinson's disease who were treated in the Second Affiliated Hospital of Henan University of Science and Technology from 2018 to 2019 were selected.They were divided into two groups with randomization principles,each with 39 patients.The control group was treated with levodopa.The observation group was treated with entacapone on the basis of the control group.The serum indexes,Parkinson score scale-Ⅱ(UPDRS-Ⅱ),UPDRS-Ⅲscores and adverse reactions were compared between the two groups.Results After treatment,the levels of interleukin-1β(IL-1β),IL-6 and malondialdehyde(MDA)in the observation group were significantly lower than those in the control group,and superoxide dismutase(SOD)and glutathione peroxidation GSH-Px levels were higher and the difference was statistically significant(P<0.05);compared with the control group after treatment,the UPDRS-Ⅱand UPDRS-Ⅲscores of the observation group were lower,and the difference was statistically significant(P<0.05);the incidence of adverse reactions in the observation group(10.25%)compared with the control group(15.38%),the difference was not statistically significant(P>0.05).Conclusion L-dopa combined with entacapone is effective in the treatment of patients with Parkinson's disease.It can effectively improve the serum level of patients and increase the score of Parkinson's scale without increasing the incidence of adverse reactions.

关 键 词：左旋多巴 恩他卡朋 帕金森病 安全性 

分 类 号：R742.5[医药卫生—神经病学与精神病学]